A Phase IB, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: I
Principal Investigator: Wildes, Tanya
Contact Information:
Melissa Eagen
meagen@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07280013?term=NCT07280013&rank=1#participation-criteria
Summary
Primary:
-To evaluate the safety and tolerability of cemsidomide in combination with elranatamab to determine the MTD or MAD
Secondary:
-To assess the antimyeloma activity of cemsidomide in combination with elranatamab
-To evaluate the PK of cemsidomide and elranatamab in combination
-To assess the immunogenicity of elranatamab when administered in combination with cemsidomide
Exploratory:
-To explore the relationship between PD biomarkers and clinical outcomes
-To assess exposure-response relationships between cemsidomide and relevant markers of safety and efficacy